Werewolf Therapeutics, Inc.

NasdaqGS HOWL

Werewolf Therapeutics, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.97

Werewolf Therapeutics, Inc. Price to Earnings Ratio (P/E) is -0.97 on January 14, 2025, a 82.73% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Werewolf Therapeutics, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.97 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
Werewolf Therapeutics, Inc. 52-week low Price to Earnings Ratio (P/E) is -9.18 on February 27, 2024, which is -848.07% below the current Price to Earnings Ratio (P/E).
Werewolf Therapeutics, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.55.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: HOWL

Werewolf Therapeutics, Inc.

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years